Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697858 | 0.81 | GAA (0.50) | GAAL3MBTL1KDM4EKMT2AALDH1A1 | |
| SCHEMBL9715915 | 0.81 | GAA (0.50) | GAAL3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL4397787 | 0.81 | GAA (0.50) | GAAL3MBTL1KDM4EKMT2AALDH1A1 | |
| SCHEMBL13225976 | 0.81 | GAA (0.50) | GAAL3MBTL1KDM4EKMT2AALDH1A1 | |
| SCHEMBL1933219 | 0.79 | GAA (0.48) | GAAL3MBTL1KDM4EKMT2AALDH1A1 | |
| SCHEMBL8599635 | 0.79 | CHRNB2 (0.32) | GAAL3MBTL1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL13225974 | 0.79 | GAA (0.48) | GAAL3MBTL1KDM4EKMT2AALDH1A1 | |
| SCHEMBL13225973 | 0.79 | GAA (0.48) | GAAL3MBTL1KDM4EKMT2AALDH1A1 | |
| SCHEMBL1231230 | 0.78 | GAA (0.47) | GAAL3MBTL1KDM4EKMT2AALDH1A1 | |
| SCHEMBL3057231 | 0.77 | GAA (0.42) | GAAL3MBTL1SLC18A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0822835-A1 | HYBRID MAGNETIC RESONANCE CONTRAST AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 1998-02-11 | — | — | EP | claimed |
| WO-1996032967-A1 | HYBRID MAGNETIC RESONANCE CONTRAST AGENTS | IMARX PHARMACEUTICAL CORPORATION (US) | 1996-10-24 | — | — | WO | claimed |
| US-5407657-A | Containing a metal chelate and a free radical nitroxide | IMARX THERAPEUTICS, INC. | 1995-04-18 | — | — | US | claimed |
| US-20110059922-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | COLBY PHARMACEUTICAL COMPANY (US) | 2011-03-10 | — | — | US | disclosed |
| EP-0822835-A1 | HYBRID MAGNETIC RESONANCE CONTRAST AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 1998-02-11 | — | — | EP | disclosed |
| WO-1996032967-A1 | HYBRID MAGNETIC RESONANCE CONTRAST AGENTS | IMARX PHARMACEUTICAL CORPORATION (US) | 1996-10-24 | — | — | WO | disclosed |
| US-5407657-A | Containing a metal chelate and a free radical nitroxide | IMARX THERAPEUTICS, INC. | 1995-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059922-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | TFAM, HSPD1, NLN | GAA 1476/4885L3MBTL1 1529/4885KDM4E 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.